Volpara Health Technologies (ASX:VHT), a global leader in software for the early detection of breast cancer, has appointed Mark Bouw to the Volpara Board of Directors as an independent, Non-Executive Director.
Mr Bouw is a highly experienced senior healthcare CEO who brings a wealth of international education and experience in strategy and growth for healthcare and technology companies. As founder and Managing Director of the Mark Bouw Group Pty Ltd., a leading boutique professional services company based in Melbourne, Australia, Mark’s clients include global C-suites, capital funds and private equity investors, and entrepreneurs. He is a visiting consultant at Stanford University’s Graduate Business School Seed Program in the United States and is a visiting mentor for Stanford’s Ignite program.
Mark’s diversity of experiences and management training will bring a unique and welcome perspective to our board as Volpara prepares for its continued growth and upcoming profitability,” said Teri Thomas, CEO and Managing Director of Volpara.
Volpara Health Technologies makes software to save families from cancer. Healthcare providers use Volpara to better understand cancer risk, empower patients in personal care decisions, and guide recommendations about additional imaging, genetic testing, and other interventions. The company’s AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality, positioning, compression, and dose. In an industry facing increasing staffing shortages, our software streamlines operations and provides key performance insights that support continuous quality improvement.
Volpara is the preferred partner of leading healthcare institutions around the world. Our software is used in over 2,000 facilities by more than 5,000 technologists, impacting nearly 15 million patients globally. It helps providers conduct more than three million cancer risk assessments each year and can be deployed stand-alone or fully integrated with electronic health record systems, mammography reporting systems, imaging hardware, and genetic laboratories.